CDx
Contact Us

Genomic Data Analysis Services

Our expert genomic data analysis services support sequencing and variant analysis, differential gene expression profiling, and spatial modalities.

Speak with Our Experts
Genomic Data Analysis Hero

Built for Complex Genomics

Turn your sequencing data into findings that hold up across studies, sites, and regulatory scrutiny.

Genomic data analysis services span all major modalities, and our services are backed by a dedicated bioinformatics team that engages directly with your research questions, then uses advanced processing and analysis methods to deliver transparent, reproducible results with the QC depth your program demands.

Our Genomic Analysis Capabilities

Profile transcriptomes using gene expression analysis software for RNAseq and NanoString nCounter®. RNA-seq pipelines cover read alignment, transcript quantification, splice variant and fusion detection, tumor immune cell fractions, and proprietary ML-based eTMB and eMSI quantification.

NanoString workflows include background correction, normalization, batch effect control, DGE, and pathway enrichment analysis.

Generate validated, auditable outputs for CAR-T development, viral vector quantification, and genome editing programs within CellCarta's genomic data analysis software infrastructure.

Quantitative PCR (qPCR) workflows use peer-reviewed models for efficiency correction, error propagation, and inter-run calibration across large sample sets. Digital PCR (dPCR) applies generalized mixed linear models for linearity and accuracy testing, delivering auditable outputs for CAR-T, viral vector quantification, and genome editing programs.

Detect variants across the full genome or coding regions with pipelines built for clinical-grade reporting. WGS by next-generation sequencing covers coding and non-coding variants, SVs, CNVs, mitochondrial variants, and repeat expansions.

WES captures over 95% of disease-associated variants with SNV, indel, CNV, MSI, and TMB analysis in tumor-only or paired tumor/normal settings across oncology, rare disease, and pharmacogenomics.

We run validated workflows for TSO500 HT, TSO500 ctDNA v2, oncoReveal® CDx, Aspyre® Lung, and HLA genotyping.

Each runs on its optimized platform — Illumina Connected Analytics, Pillar's RUO Suite and IVD Workstation, or Aspyre Lab — with automated QC, variant calling, annotation, and biomarker computation. ctDNA v2 detects variants at allele frequencies as low as 0.5% for MRD assessment and longitudinal monitoring.

Resolve cellular heterogeneity and immune repertoire dynamics using the 10x Genomics Chromium platform and Cell Ranger software.

The pipeline supports 5' gene expression, V(D)J, and feature barcode libraries through alignment, clustering, cell-type annotation, trajectory inference, and pathway enrichment. CellEngine extends this with flow cytometry-style visualization, tSNE/UMAP gating, and multi-patient secondary analysis.

Map gene expression in tissue context using genomic data analysis software across our spatial platforms, including GeoMx and Visium HD . GeoMx pipelines include ROI selection, QC, and digital pathology integration.

Visium HD uses Space Ranger for spatial alignment, normalization, clustering, and domain detection. Advanced capabilities include batch correction, cell type deconvolution using reference atlases, and gene signature enrichment.

Combine your datasets across several fields using our in-house multi-omic analysis capabilities, enabling a more in-depth understanding of your study’s complex biological questions.

Our data analysis pipeline combines RNA sequencing data with spatial transcriptomic analysis and spatial proteomics, enabling multidimensional tumor profiling.

Profile transcriptomes using gene expression analysis software for RNAseq and NanoString nCounter®. RNA-seq pipelines cover read alignment, transcript quantification, splice variant and fusion detection, tumor immune cell fractions, and proprietary ML-based eTMB and eMSI quantification.

NanoString workflows include background correction, normalization, batch effect control, DGE, and pathway enrichment analysis.

Gene Expression Tab 488

Generate validated, auditable outputs for CAR-T development, viral vector quantification, and genome editing programs within CellCarta's genomic data analysis software infrastructure.

Quantitative PCR (qPCR) workflows use peer-reviewed models for efficiency correction, error propagation, and inter-run calibration across large sample sets. Digital PCR (dPCR) applies generalized mixed linear models for linearity and accuracy testing, delivering auditable outputs for CAR-T, viral vector quantification, and genome editing programs.

Scientist operating benchtop PCR instrument.

Detect variants across the full genome or coding regions with pipelines built for clinical-grade reporting. WGS by next-generation sequencing covers coding and non-coding variants, SVs, CNVs, mitochondrial variants, and repeat expansions.

WES captures over 95% of disease-associated variants with SNV, indel, CNV, MSI, and TMB analysis in tumor-only or paired tumor/normal settings across oncology, rare disease, and pharmacogenomics.

Scientists performing sequencing in a genomics laboratory.

We run validated workflows for TSO500 HT, TSO500 ctDNA v2, oncoReveal® CDx, Aspyre® Lung, and HLA genotyping.

Each runs on its optimized platform — Illumina Connected Analytics, Pillar's RUO Suite and IVD Workstation, or Aspyre Lab — with automated QC, variant calling, annotation, and biomarker computation. ctDNA v2 detects variants at allele frequencies as low as 0.5% for MRD assessment and longitudinal monitoring.

Scientist loading samples into a benchtop instrument.

Resolve cellular heterogeneity and immune repertoire dynamics using the 10x Genomics Chromium platform and Cell Ranger software.

The pipeline supports 5' gene expression, V(D)J, and feature barcode libraries through alignment, clustering, cell-type annotation, trajectory inference, and pathway enrichment. CellEngine extends this with flow cytometry-style visualization, tSNE/UMAP gating, and multi-patient secondary analysis.

Loading a sample into the 10X Genomics Chromium instrument.

Map gene expression in tissue context using genomic data analysis software across our spatial platforms, including GeoMx and Visium HD . GeoMx pipelines include ROI selection, QC, and digital pathology integration.

Visium HD uses Space Ranger for spatial alignment, normalization, clustering, and domain detection. Advanced capabilities include batch correction, cell type deconvolution using reference atlases, and gene signature enrichment.

Scientist analyzing tissue sections for spatial transcriptomics on a GeoMx DSP.

Combine your datasets across several fields using our in-house multi-omic analysis capabilities, enabling a more in-depth understanding of your study’s complex biological questions.

Our data analysis pipeline combines RNA sequencing data with spatial transcriptomic analysis and spatial proteomics, enabling multidimensional tumor profiling.

Multi Modal Analysis Tab 305
167 Scalable Data Delivery

Secure, Scalable Data Delivery

Secure, scalable solutions for raw and processed data transfers via AWS S3 exchange buckets, SFTP, or proprietary platforms. We deliver raw sequencing data, pipeline outputs, downstream-processed results, and customizable metadata aligned with your specifications. Our internal archiving policy stores and retrieves project data for up to 25 years and provides flexibility to access or reshare results long after initial delivery.

Why CellCarta

Rigorous, reproducible genomic analysis built for translational and clinical programs.

Expert Bioinformatics

Proprietary ML Pipelines

Full-Modality Coverage

Reproducible Pipelines

Regulatory-Grade QC

Ready to Discuss Your Genomic Program?

Partner with a team that combines proven genomic data analysis services and infrastructure with expert bioinformatics support to deliver accurate, reproducible insights.

Cta Banner CellCarta 527

Frequently Asked Questions

CellCarta's genomic data analysis services support every major sequencing and molecular modality used in translational and clinical programs: RNA-seq, whole genome and whole exome sequencing, quantitative and digital PCR, single-cell sequencing, spatial biology, and validated off-the-shelf assays, including TSO500, oncoReveal CDx, and Aspyre Lung. Each modality is delivered by an in-house bioinformatics team that applies rigorous QC, transparent pipelines, and advanced methods, including machine-learning–based biomarker quantification.
CellCarta's gene expression analysis services capabilities cover RNA-seq and NanoString nCounter workflows for biomarker discovery, validation, and clinical deployment. RNA-seq pipelines include read alignment, transcript quantification, splice variant and fusion detection, tumor immune cell fraction analysis, and proprietary ML-based eTMB and eMSI quantification. NanoString workflows include background correction, normalization, batch effect control, differential gene expression, and pathway enrichment — supporting biomarker programs from translational research through late-stage clinical trials.
Yes — and this is one of the clearest advantages of working with CellCarta. Our genomic data analysis services operate within an integrated multi-omic infrastructure rather than as a standalone genomics offering. Genomic findings can be correlated with immune monitoring, flow cytometry, spatial biology, histopathology, and proteomics data, all generated under a single quality framework. For complex clinical programs where cross-modal biomarker correlation drives the science, this removes the integration burden sponsors typically carry across multiple vendors.
Yes. CellCarta's genomic data analysis services operate within a fully governed quality management system spanning GLP, CLIA, CAP, ISO 15189, and ISO 13485. Pipelines and outputs are built to support both exploratory research and regulated submissions — including primary endpoints, IVD performance studies, and companion diagnostic programs — and every output is produced under the same quality framework across our global sites.